Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Ioline D. Henter, Lawrence T. Park, Carlos A. Zarate
CNS Drugs (2021) Vol. 35, Iss. 5, pp. 527-543
Open Access | Times Cited: 108

Showing 26-50 of 108 citing articles:

Emerging Treatments for Bipolar Disorder
Nefize Yalın, Allan H. Young, Carlos A. Zarate
Oxford University Press eBooks (2025), pp. 329-346
Closed Access
Emerging Medications for Treatment-Resistant Depression: A Review with Perspective on Mechanisms and Challenges
Michael J. Lucido, Boadie W. Dunlop
Brain Sciences (2025) Vol. 15, Iss. 2, pp. 161-161
Open Access
Ion Channel Disturbances in Migraine Headache: Exploring the Potential Role of the Kynurenine System in the Context of the Trigeminovascular System
Eleonóra Spekker, Gábor Nagy-Grócz, László Vécsei
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 23, pp. 16574-16574
Open Access | Times Cited: 11
Peripheral inflammation triggering central anxiety through the hippocampal glutamate metabolized receptor 1
Jun‐Meng Wang, Yue‐Mei Wang, Yuanbing Zhu, et al.
CNS Neuroscience & Therapeutics (2024) Vol. 30, Iss. 4
Open Access | Times Cited: 4
Depression clinical trials worldwide: a systematic analysis of the ICTRP and comparison with ClinicalTrials.gov
Eugenia D. Namiot, Diana Smirnovová, Aleksandr V. Sokolov, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Glutamatergic Modulators for Major Depression from Theory to Clinical Use
Roger S. McIntyre, Rakesh Jain
CNS Drugs (2024) Vol. 38, Iss. 11, pp. 869-890
Open Access | Times Cited: 4
The gut microbiome and the brain
N. A. Rykalo, Lydia Riehl, Michaela Kress
Current Opinion in Supportive and Palliative Care (2024)
Closed Access | Times Cited: 4
Esketamine alleviates depressive-like behavior in neuropathic pain mice through the METTL3-GluA1 pathway
Xiaoming Ji, Zhimin Huang, Chenming Zhou, et al.
Cell Biology and Toxicology (2025) Vol. 41, Iss. 1
Open Access
Overcoming Mycobacterium tuberculosis through small molecule inhibitors to break down cell wall synthesis
Wenbin Kuang, Haolin Zhang, Xiao Wang, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 8, pp. 3201-3214
Open Access | Times Cited: 18
Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia
Tanja Veselinović, Irene Neuner
CNS Drugs (2022) Vol. 36, Iss. 8, pp. 819-858
Open Access | Times Cited: 17
Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism
Andrzej Pilc, Agata Machaczka, Paweł Kawalec, et al.
Expert Opinion on Drug Discovery (2022) Vol. 17, Iss. 10, pp. 1131-1146
Closed Access | Times Cited: 17
Postsynaptic Proteins at Excitatory Synapses in the Brain—Relationship with Depressive Disorders
Sylwia Samojedny, Ewelina Czechowska, Patrycja Pańczyszyn-Trzewik, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11423-11423
Open Access | Times Cited: 17
The safety and efficacy of ketamine NMDA receptor blocker as a therapeutic intervention for PTSD review of a randomized clinical trial
Wisam Al Jumaili, Chintan Trivedi, Timothy Chao, et al.
Behavioural Brain Research (2022) Vol. 424, pp. 113804-113804
Closed Access | Times Cited: 16
A systematic review and meta-analysis of the efficacy of ketamine and esketamine on suicidal ideation in treatment-resistant depression
Yating Wang, Xiaole Wang, Lei Lan, et al.
European Journal of Clinical Pharmacology (2023) Vol. 80, Iss. 2, pp. 287-296
Closed Access | Times Cited: 9
The role and mechanism of esketamine in preventing and treating remifentanil-induced hyperalgesia based on the NMDA receptor–CaMKII pathway
Jiafang Wang, Yankun Feng, Qi Zhong, et al.
Open Life Sciences (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 3
Repurposing Ketamine in the Therapy of Depression and Depression-Related Disorders: Recent Advances and Future Potential
Qianting Deng, Emily D. Parker, Chongyun Wu, et al.
Aging and Disease (2024)
Open Access | Times Cited: 3
Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?
Aistė Lengvenytė, Robertas Strumila, Émilie Olié, et al.
European Neuropsychopharmacology (2022) Vol. 57, pp. 88-104
Open Access | Times Cited: 15
Discovery of (R)-N-Benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide [(R)-AS-1], a Novel Orally Bioavailable EAAT2 Modulator with Drug-like Properties and Potent Antiseizure Activity In Vivo
Michał Abram, Marcin Jakubiec, Katelyn Reeb, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 17, pp. 11703-11725
Open Access | Times Cited: 15
Elevation of Extracellular Glutamate by Blockade of Astrocyte Glutamate Transporters Inhibits Cocaine Reinforcement in Rats via a NMDA-GluN2B Receptor Mechanism
Hongju Yang, Briana J. Hempel, Guo‐Hua Bi, et al.
Journal of Neuroscience (2022) Vol. 42, Iss. 11, pp. 2327-2343
Open Access | Times Cited: 13
New investigational agents for the treatment of major depressive disorder
Bartłomiej Pochwat, Anna Julia Krupa, Marcin Siwek, et al.
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 10, pp. 1053-1066
Closed Access | Times Cited: 13
Brachial plexus avulsion induced changes in gut microbiota promotes pain related anxiety-like behavior in mice
Jianlei Zhang, Hang Xian, Rui Zhao, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 7
A Critical View on New and Future Antidepressants
Alessandro Serretti
Clinical Psychopharmacology and Neuroscience (2024) Vol. 22, Iss. 2, pp. 201-210
Open Access | Times Cited: 2
Repurposing of dextromethorphan as an adjunct therapy in patients with major depressive disorder: a randomised, group sequential adaptive design, controlled clinical trial protocol
Shampa Maji, Debadatta Mohapatra, Monalisa Jena, et al.
BMJ Open (2024) Vol. 14, Iss. 4, pp. e080500-e080500
Open Access | Times Cited: 2
Drugs with glutamate-based mechanisms of action in psychiatry
Adrian Andrzej Chrobak, Marcin Siwek
Pharmacological Reports (2024)
Open Access | Times Cited: 2
(2R,6R)-hydroxynorketamine rapidly potentiates optically-evoked Schaffer collateral synaptic activity
Lace M. Riggs, Scott M. Thompson, Todd D. Gould
Neuropharmacology (2022) Vol. 214, pp. 109153-109153
Open Access | Times Cited: 11

Scroll to top